FibroGen, Inc.
FibroGen is a biopharmaceutical company discovering and developing potential first-in-class therapeutics for anemia, fibrotic disease, and cancer. Pamrevlumab is an investigational human monoclonal antibody that specifically binds to and inhibits the effects of connective tissue growth factor (CTGF) and currently being studied in a Phase 3 clinical trial in patients with locally advanced unresectable pancreatic cancer. Pamrevlumab is also being studied in patients with idiopathic pulmonary fibrosis and Duchenne muscular dystrophy. Please visit www.fibrogen.com for additional information.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No